

Republic of the Philippines Department of Health

Food And Drug Administration



Civic Drive, Filinvest Corporate City, Alabang, Muntinlupa Food and Drug Administration City

Notification of Cosmetic Product

Pursuant to the existing rules and regulations of the Food and Drug Administration (FDA) for the notification of cosmetics, the product notification is hereby acknowledged,

Cosmetic Notification Number: NN-1000006414086

Validity: 17 July 2023

Particulars of the Product

Brand Name: ECZEKLEEN DUO

Product Name: ECZEKLEEN DUO BARRIER REPLENISHING CREAM

Variant/s: N/A

Particulars of the Manufacturer

Name of the Manufacturer: ARB LABORATORIES INC.

Address of the Manufacturer: Lot # 15 North Zuzuaregui St., Old Balara, Quezon City, Metro

Manila Manila

Country of Manufacture: Philippines

Particulars of the Local Company Responsible for Placing the Product in the Market

Name of the Company: ESKEEN LABORATORIES INC.

Address of the Company:

UG-1 STAR CENTRUM CONDOMINIUM, GIL PUYAT

AVE. CORNER MALLICAN ST. REL. AIR MAKATI CITE

AVE., CORNER MALUGAY ST., BEL-AIR, MAKATI CITY

LTO Number: LTO-3000001771311

The product is allowed to be sold in the local market subject to compliance with the requirements of the ASEAN Cosmetic Directive and the FDA laws, and its implementing rules and regulations. This notification should not be taken as a guarantee and/or endorsement of the safety, quality, and claimed benefit of the product. Any subsequent changes to the information submitted in this notification will render this notification invalid and a new notification will have to be submitted.

The company hereby ensures that they shall respond and cooperate fully with the FDA with regard to any subsequent post-marketing activity initiated by the FDA. Further, the company shall be responsible for ensuring that each consignment of the product continues to meet all the legal requirements, and conforms to all the standards and specifications of the product declared to the FDA.

This authorization is subject to suspension, cancellation, or recall should any violation of FDA laws, and its implementing rules and regulations, involving the product be committed.

BY AUTHORITY OF THE ACTING DIRECTOR GENERAL

Engr. Ana Trinidad F. Rivera, MSc

Director IV/Center for Cosmetic Regulation and Research